Mirae Asset Global Investments Co. Ltd. Has $18.87 Million Holdings in Stryker Corporation $SYK

Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Stryker Corporation (NYSE:SYK) by 12.4% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 51,038 shares of the medical technology company’s stock after buying an additional 5,623 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Stryker were worth $18,867,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Mid American Wealth Advisory Group Inc. acquired a new position in shares of Stryker during the 2nd quarter valued at about $26,000. Clayton Financial Group LLC bought a new stake in Stryker during the third quarter worth approximately $26,000. Elevation Point Wealth Partners LLC acquired a new position in Stryker during the second quarter valued at approximately $28,000. Sachetta LLC raised its position in shares of Stryker by 58.7% in the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after purchasing an additional 27 shares during the period. Finally, Kilter Group LLC acquired a new stake in shares of Stryker in the second quarter worth $29,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker News Roundup

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Quarterly beat: Stryker reported adjusted Q4 EPS $4.47 and revenue $7.17B, topping consensus on both measures — a clear near‑term positive for revenue and profitability trends. Stryker (SYK) Surpasses Q4 Earnings and Revenue Estimates
• Positive Sentiment: Raised profit outlook: Management raised its full‑year profit forecast, citing strong implant and capital product demand — a catalyst for forward earnings expectations. Stryker raises annual profit forecast on strong sales for medical devices
• Positive Sentiment: Solid full‑year momentum and guidance: FY2025 adjusted EPS and margins expanded (adjusted EPS $13.63; adjusted operating margin +100 bps year) and management guided 2026 organic net‑sales growth ~8.0%–9.5% with adjusted EPS $14.90–$15.10 — supports medium‑term upside. Stryker reports 2025 operating results and 2026 outlook
• Neutral Sentiment: Analyst/street context: Several firms maintain positive ratings (e.g., Piper Sandler reaffirmed a Buy), and sell‑side median targets remain well above the current price — supports sentiment but may already be priced in. Piper Sandler Remains a Buy on Stryker (SYK)
• Neutral Sentiment: Conference call / details ahead: Management held an earnings call and provided granular segment math and non‑GAAP reconciliations — useful for modeling but unlikely to shift the stock absent new guidance tweaks. Press release & conference details
• Negative Sentiment: Mixed segment dynamics: MedSurg & Neuro showed double‑digit growth, but spinal implants and some orthopaedics subcategories remain weak or volatile — a potential drag on sustained top‑line upside. Stryker Reports Strong Q4 and Full-Year 2025 Results
• Negative Sentiment: One‑offs and legacy charges: Prior goodwill impairments, tax adjustments and other special items still affect GAAP comparisons and introduce modeling uncertainty — some investors may be trimming positions until recurring earnings visibility is clearer. Full release: reconciliations and note on adjustments
• Negative Sentiment: Valuation and profit‑taking risk: SYK trades at a premium P/E (~46 on reported metrics) and recent insider selling activity may encourage short‑term profit‑taking despite the beat. Analyst comparison & metrics

Stryker Stock Down 1.0%

NYSE SYK opened at $354.39 on Friday. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $404.87. The stock has a market cap of $135.52 billion, a PE ratio of 46.57, a PEG ratio of 2.29 and a beta of 0.89. The firm has a 50-day simple moving average of $359.38 and a 200 day simple moving average of $371.95. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.13 and a current ratio of 1.85.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, beating the consensus estimate of $4.40 by $0.07. Stryker had a return on equity of 24.07% and a net margin of 12.07%.The firm had revenue of $7.17 billion during the quarter, compared to analysts’ expectations of $7.12 billion. During the same quarter in the prior year, the firm posted $4.01 EPS. The company’s revenue for the quarter was up 11.4% on a year-over-year basis. On average, research analysts forecast that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Wednesday, December 31st will be paid a dividend of $0.88 per share. This is an increase from Stryker’s previous quarterly dividend of $0.84. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Wednesday, December 31st. Stryker’s dividend payout ratio is presently 46.25%.

Analysts Set New Price Targets

Several research analysts recently commented on SYK shares. BTIG Research reiterated a “buy” rating and issued a $410.00 target price on shares of Stryker in a report on Friday, November 14th. UBS Group set a $408.00 price target on Stryker in a research report on Monday, October 13th. Wells Fargo & Company boosted their price objective on Stryker from $452.00 to $456.00 and gave the stock an “overweight” rating in a research report on Friday, November 14th. Truist Financial decreased their target price on Stryker from $400.00 to $392.00 and set a “hold” rating for the company in a research note on Thursday, December 18th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $448.00 price target on shares of Stryker in a research report on Friday, November 14th. Twelve investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $425.94.

Insider Buying and Selling at Stryker

In other news, CAO William E. Berry, Jr. sold 1,953 shares of the stock in a transaction on Friday, November 14th. The shares were sold at an average price of $365.49, for a total value of $713,801.97. Following the completion of the transaction, the chief accounting officer owned 2,833 shares in the company, valued at approximately $1,035,433.17. This represents a 40.81% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Ronda E. Stryker sold 276,173 shares of Stryker stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the sale, the director owned 2,702,108 shares in the company, valued at approximately $954,600,714.24. This trade represents a 9.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 522,118 shares of company stock valued at $185,381,932 in the last 90 days. 5.90% of the stock is currently owned by company insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.